X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Low-Dose COVID Vaccine From Moderna Safe For Kids Under Six

Content Team by Content Team
25th March 2022
in News
Moderna To introduce The Fusion Of COVID-19 And Flu Booster

Moderna has published the mid-term findings of its COVID-19 vaccination for children under the age of six. Two 25-microgram doses of the COVID-19 vaccine for kids aged 6 months to 5 years old generated an immune response comparable to two 100-microgram doses for adults aged 18 to 25, indicating that the advantage imparted on young adults is also conferred on young children, according to the company. The vaccination is administered to children in two doses, 28 days apart.

According to a corporate news release issued, the data showed a significant neutralising immune reaction and a positive safety profile. The pharma giant has confirmed that it will pursue the US FDA in few weeks to approve the vaccine’s use in this younger age range based on the evidence.

Moderna CEO Stéphane Bancel said that given the need for a vaccination against COVID-19 in newborns and young children, they are collaborating with the US FDA and regulators around the world to submit these findings as quickly as feasible. These current findings appear to be highly favourable for parents with kids under the age of six.

The vaccine was insufficient to prevent COVID-19 infections caused by the Omicron strain, which was common in the US at the time of the study. The effectiveness was 43.7 percent for children aged 6 months to one year.

The performance was 37.5 percent for children aged 2 to 5. The less efficient outcome was nonetheless statistically significant, according to Moderna, and comparable to how vaccinated individuals had fared with the Omicron version.

Moderna said it is planning to assess the possibility of a booster shot for all kids aged 6 months and up, which would target both the original strain and the Omicron type of the virus. The figures are based on a sample of 6,900 kids aged 6 months to 5 years old. The majority of side effects are mild to moderate, and they become more common after the second dose. According to Moderna, no deaths or instances of myocarditis or pericarditis have been documented. It is well to be noted that the infection of the heart muscle is myocarditis, while the infection of the heart membrane is pericarditis. The company also stated that it has started the process of applying to the FDA for urgent use authorisation of its COVID-19 vaccine for children aged 6 to 11. Two doses of a bigger 50-microgram form of the vaccine would be given to children of that age. Moderna also stated that it provided further follow-up statistics on its vaccination for youngsters aged 12 to 17 to the FDA. Two doses of a bigger 100-microgram form of the vaccine would be given to children in that bracket.

The FDA delayed a meeting of its vaccine advisors last month to discuss Pfizer and BioNTech’s vaccine for children under the age of five and asked for further evidence on third doses. The companies have stated that the data will be available in early April.

Previous Post

Pharmaceutical Branded Market Keeps Making Headways In China

Next Post

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine. Candidate, CV2CoV

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine. Candidate, CV2CoV

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In